STAT

NOVEMBER 23, 2023

Reports of increased respiratory disease among children in China have put disease watchers elsewhere on alert, triggering anxiety that the outbreak — if it is indeed one outbreak — holds uncomfortable echoes of the start of the Covid-19 pandemic. But at present, a number of experts say the activity has a likely explanation: China’s population, especially its young children, probably developed significant immunological susceptibility to a range of respiratory pathogens d

145

145

Pharmacy Times

NOVEMBER 23, 2023

Pediatric individuals that are higher risk for APS must be followed to better understand affects

145

145

pharmaphorum

NOVEMBER 23, 2023

AstraZeneca joins KRAS push in cancer with Chinese deal Phil.

130

130

European Pharmaceutical Review

NOVEMBER 23, 2023

Boehringer Ingelheim is acquiring Swiss biotech T3 Pharmaceuticals AG (T3 Pharma), for up to £406 million (450 million CHF), boosting its immuno-oncology portfolio. The pharmaceutical company will utilise T3 Pharmaceutical’s proprietary bacterial cancer therapy platform that consisting that delivers immune-modulating bioactive proteins to cancer cells and tumour micro-environments.

Pharmaceutical Companies 115

Pharmaceutical Companies Pharmaceutical Companies Immunization Vaccines 115

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patient Care

pharmaphorum

NOVEMBER 23, 2023

How can the value of patient engagement be quantified and measured? Mike.

124

124

European Pharmaceutical Review

NOVEMBER 23, 2023

Following the UK government’s recent announcement of a £520 million funding boost for UK manufacturing, a new Oligonucleotide Manufacturing Innovation Centre of Excellence in Scotland will develop innovative and sustainable techniques for these medicines. According to the Centre for Process Innovation (CPI), oligonucleotides therapeutics use short, chemically synthesised fragments of DNA or RNA to modulate protein expression and ultimately treat the underlying cause of disease.

Packaging 104

Packaging 104

Drug Topics

NOVEMBER 23, 2023

While data has associated insufficient sleep with increased risks of hypertension, cardiovascular disease, and disordered glucose metabolism, a potential source of insulin resistance and type 2 diabetes, much of this data was performed on male participants or evaluated short-term sleep restriction.

98

98

pharmaphorum

NOVEMBER 23, 2023

The power of data science platforms to cut through the complexity of modern-day clinical research Mike.

119

119

Drug Topics

NOVEMBER 23, 2023

The federal agencies said that they will continue to work closely with manufacturers to maintain the availability of the vaccines through the end of 2023 and early 2024 to meet the demand during the RSV season.

Vaccines 98

Vaccines FDA 98

pharmaphorum

NOVEMBER 23, 2023

How birth tissue donations are fuelling the cell therapy revolution Mike.

116

116

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Pharmaceutical Technology

NOVEMBER 23, 2023

T3 Pharma uses a bacterial secretion system for the delivery of immune-modulating proteins to cancer cells and tumour micro-environments.

Immunization 96

Immunization 96

pharmaphorum

NOVEMBER 23, 2023

Supercharge your supply chain: Harnessing AI to gain competitive advantage Mike.

111

111

European Pharmaceutical Review

NOVEMBER 23, 2023

Last month at CPHI Barcelona 2023 , EPR interviewed Mohamed Noor, Digitalization Manager at the National Institute for Bioprocessing Research and Training ( NIBRT ). During the conversation, Noor shed light on how digitalisation is impacting the biopharmaceutical industry. Additionally, he explored the trends, challenges and opportunities for process analytical technology (PAT).

93

93

pharmaphorum

NOVEMBER 23, 2023

Novo Nordisk will invest €2.1bn in French manufacturing site Phil.

110

110

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

Outsourcing Pharma

NOVEMBER 23, 2023

Cradle, the biotech startup using generative AI to help scientists design and engineer proteins, has raised $24 million in Series A funding.

82

82

pharmaphorum

NOVEMBER 23, 2023

US biotech Moderna has completed the installation of its clinical laboratories at its new R&D facility in the UK dedicated to the discovery of new mRNA vaccines and therapeutics, part of a 10-year partnership with the government agreed last year that has been estimated to be worth around £1 billion.

Vaccines 105

Vaccines 105

Outsourcing Pharma

NOVEMBER 23, 2023

German CDMO Adragos Pharma has its eye on expansion and is continually branching out into new markets.

78

78

pharmaphorum

NOVEMBER 23, 2023

InDex craters on phase 3 ulcerative colitis failure Phil.

104

104

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

Outsourcing Pharma

NOVEMBER 23, 2023

Healthcare breakthroughs have long-standing barriers when it comes to unlocking the powerful insights trapped in medical imaging data.

74

74

pharmaphorum

NOVEMBER 23, 2023

Lord James O’Shaughnessy has welcomed the UK government’s official response to his review of commercial clinical trials, saying there have been a number of positive developments since it was published in the spring.

95

95

Pharmaceutical Technology

NOVEMBER 23, 2023

EirGenix and Sandoz's biosimilar has been approved for all the indications as the reference biologic, Roche’s Herceptin.

59

59

BioPharm

NOVEMBER 23, 2023

Chris Spivey, editorial director for Pharmaceutical Technology and Biopharm International, spoke with Concetto Andrea Rizza, Marketing and Communications manager, ICE Pharma, on sustainability and ICE’s green approach at CPhI Barcelona 2023.

Communication 59

Communication 59

Pharmaceutical Technology

NOVEMBER 23, 2023

The fast track designation for the paediatric multi-food allergy therapy ADP101 was based on the Phase I/II data.

FDA 59

FDA 59

Pharmafile

NOVEMBER 23, 2023

MorphoSys has announced topline results from its phase 3 MANIFEST-2 study, which assessed pelabresib, an investigational BET inhibitor, in combination with ruxolitinib, a JAK inhibitor for the treatment of JAK inhibitor-naïve patients with myelofibrosis. The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in the proportion of patients achieving at […] The post MorphoSys shares phase 3 trial results for pelabresib in myelofibro

59

59

Pharma Times

NOVEMBER 23, 2023

ADP101 is an oral immunotherapy to treat multi-food and single-food allergies - News - PharmaTimes

FDA 54

FDA 54

Pharmafile

NOVEMBER 23, 2023

Landos Biopharma has announced that it has shared safety, tolerability, pharmacokinetics and clinical efficacy results for the NX-13 phase 1b trial for patients with ulcerative colitis (UC), having published this data in the Journal of Crohn’s and Colitis. The trial included 38 patients, with the patients randomised to either receive various doses of the NX-13 […] The post Landos Biophama shares results from phase 1b trial for ulcerative colitis treatment appeared first on Pharmafile.

59

59

Pharma Times

NOVEMBER 23, 2023

Both companies will use their platforms to accelerate drug discovery and development - News - PharmaTimes

54

54

BioPharm

NOVEMBER 23, 2023

Hovione has acquired start-up company, ExtremoChem, expanding its technology platforms.

52

52

Pharmaceutical Technology

NOVEMBER 23, 2023

Simcere will have the rights to develop and commercialise rademikibart in mainland China, Macau, Taiwan, and Hong Kong.

52

52

BioPharm

NOVEMBER 23, 2023

UK industry body, ABPI, has responded positively to the recent Autumn Statement.

52

52

Hospital Pharmacy Europe

NOVEMBER 23, 2023

Zanubrutinib (brand name Brukinsa) has been granted marketing authorisation by the European Commission (EC) for use in combination with obinutuzumab for eligible patients with follicular lymphoma, its manufacturer BeiGene has announced. This highly selective, oral Bruton’s tyrosine kinase (BTK) inhibitor is now approved for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma who have received at least two prior lines of systemic therapy.

Labelling 52

Labelling Chemotherapy Hospitals 52

Pharmaceutical Technology

NOVEMBER 23, 2023

Syncona has signed a definitive agreement to acquire clinical-stage biotechnology company Freeline Therapeutics

52

52

Hospital Pharmacy Europe

NOVEMBER 23, 2023

A low-carbon salbutamol metered-dose inhaler (MDI) that could reduce greenhouse gas emissions from use of the inhaler by around 90% is to advance to phase 3 trials in the first half of 2024. If successful, the phase 3 trials will support regulatory submissions in 2025, its manufacturer GSK has said. The low-carbon salbutamol inhaler uses a next-generation propellant technology, which has been under technical development for several years and has been tested extensively to ensure suitability for

Hospitals 52

Hospitals 52